{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:05:45Z","timestamp":1774555545250,"version":"3.50.1"},"reference-count":53,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma"},{"name":"Janssen, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.2217\/imt.14.109","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T14:02:44Z","timestamp":1424872964000},"page":"73-87","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Progress in Biosimilar Monoclonal Antibody Development: the Infliximab Biosimilar Ct-P13 in the Treatment of Rheumatic Diseases"],"prefix":"10.1080","volume":"7","author":[{"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet,\rClaudiusstr. 45,\r44649\rHerne, & Ruhr Universit\u00e4t Bochum,\rGermany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Kudrin","sequence":"additional","affiliation":[{"name":"CELLTRION Inc.,\rIncheon,\rSouth Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,2,25]]},"reference":[{"issue":"9","key":"e_1_3_3_3_1","first-page":"S3","article-title":"Core management principles in rheumatoid arthritis to help managed care professionals","volume":"17","author":"Agarwal SK.","year":"2011","unstructured":"Agarwal SK. Core management principles in rheumatoid arthritis to help managed care professionals. Manag. Care Pharm.17(9-b), S3\u2013S8 (2011).","journal-title":"Manag. Care Pharm."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30505"},{"key":"e_1_3_3_5_1","unstructured":"IMS Institute for Health Care Informatics . The global use of medicines: Outlook Through 2016. www.imshealth.com"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2307"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3310"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11593730-000000000-00000"},{"issue":"4","key":"e_1_3_3_9_1","first-page":"S102","article-title":"Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues","volume":"30","author":"Lapadula G","year":"2012","unstructured":"Lapadula G , FerraccioliGF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin. Exp. Rheumatol.30(4 Suppl. 73), S102\u2013S106 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1741134312470444"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1839"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202715"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203198"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMhle0706973"},{"key":"e_1_3_3_15_1","unstructured":"WHO . Guidelines on evaluation of similar biotherapeutic products (SBPs). www.who.int"},{"key":"e_1_3_3_16_1","unstructured":"EMA. Committee for Medicinal Products for Human Use (CHMP) . Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Draft (2013). www.ema.europa.eu"},{"key":"e_1_3_3_17_1","unstructured":"EMA . Committee for Medicinal Products for Human Use (CHMP). Assessment report: Inflectra (infliximab) (2013). www.ema.europa.eu"},{"key":"e_1_3_3_18_1","unstructured":"US FDA . Quality considerations in demonstrating biosimilarity to a reference protein product: draft guidance (2012). www.fda.gov"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565150-00014"},{"key":"e_1_3_3_20_1","first-page":"359","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"6","author":"Braun J","unstructured":"Braun J , BrandtJ, ListingJet al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet6, 359 (9313), 1187\u20131193 (2002).","journal-title":"Lancet"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746080-00002"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"e_1_3_3_24_1","volume-title":"14th Annual Congress of the European League Against Rheumatism.","author":"Park W","unstructured":"Park W , JaworskiJ, BrzezickiJet al. A randomised, double-blind, parallel-group, Phase 1 study comparing the pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the PLANETAS study. Presented at: 14th Annual Congress of the European League Against Rheumatism.Madrid, Spain, 12\u201315 June 2013 (Abstract no. FRI0421)."},{"key":"e_1_3_3_25_1","volume-title":"14th Annual Congress of the European League Against Rheumatism.","author":"Yoo DH","unstructured":"Yoo DH , RacewiczA, BrzezickiJet al. A Phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Presented at: 14th Annual Congress of the European League Against Rheumatism.Madrid, Spain, 12\u201315 June 2013 (Abstract no. OP0068)."},{"key":"e_1_3_3_26_1","volume-title":"ACR\/ARHP Annual Meeting.","author":"Park W","unstructured":"Park W , MirandaP, BrzoskoMet al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Presented at: ACR\/ARHP Annual Meeting.San Diego, CA, USA, 26\u201330 October 2013 (Abstract no. L15)."},{"key":"e_1_3_3_27_1","volume-title":"ACR\/ARHP Annual Meeting.","author":"Yoo DH","unstructured":"Yoo DH , ProdanavicN, JaowrskiJet al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Presented at: ACR\/ARHP Annual Meeting.San Diego, CA, USA, 26\u201330 October 2013 (Abstract no. L15)."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24408"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203201"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.6"},{"key":"e_1_3_3_31_1","unstructured":"EMA . Remsima: summary of product characteristics (2013). www.ema.europa.eu"},{"key":"e_1_3_3_32_1","unstructured":"EMA . Inflectra: summary of product characteristics (2013). www.ema.europa.eu"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20568"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.003"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.11.026"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202603"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203819"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.1464"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.1465"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/327120"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.01.022"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.03.011"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002702"},{"key":"e_1_3_3_55_1","first-page":"41","article-title":"Value of drug level testing and antibody assays in optimising biological therapy","volume":"4","author":"Vermeire S","year":"2013","unstructured":"Vermeire S , GilsA. Value of drug level testing and antibody assays in optimising biological therapy. Gastroenterology4, 41\u201343 (2013).","journal-title":"Gastroenterology"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.14.109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T20:37:11Z","timestamp":1715978231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.14.109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.2217\/imt.14.109"],"URL":"https:\/\/doi.org\/10.2217\/imt.14.109","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}